Pfizer Interest Expense 2011-2026 | PFE

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Pfizer

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
2.67 B	3.09 B	2.21 B	1.24 B	1.29 B	1.45 B	1.57 B	1.32 B	1.27 B	1.19 B	1.2 B	1.36 B	1.41 B	1.52 B	1.68 B

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.09 B	1.19 B	1.63 B

Quarterly Interest Expense Pfizer

2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
652 M	654 M	654 M	783 M	778 M	790 M	695 M	508 M	318 M	-	311 M	293 M	322 M	-	325 M	316 M	336 M	-	345 M	367 M	390 M	-	409 M	389 M	361 M	-	310 M	326 M	310 M	-	320 M	312 M	309 M	-	291 M	292 M	306 M	-	278 M	278 M	309 M	-	343 M	343 M	321 M	-	340 M	356 M	371 M	-	381 M	378 M	390 M	-	423 M	404 M	458 M

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
790 M	278 M	403 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	-2.71 M	$ 3.44	-4.32 %	$ 1.03 B	Canada
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
ADMA Biologics ADMA	-212 K	$ 15.36	-2.17 %	$ 3.66 B	USA
Cellectis S.A. CLLS	371 K	$ 3.53	-3.54 %	$ 116 M	France
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Apellis Pharmaceuticals APLS	-133 K	$ 20.28	0.65 %	$ 2.56 B	USA
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Alpine Immune Sciences ALPN	476 K	-	-	$ 2.17 B	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.51	1.35 %	$ 385 M	Britain
China SXT Pharmaceuticals SXTC	1.62 M	$ 2.01	-1.36 %	$ 2.86 M	China
Galmed Pharmaceuticals Ltd. GLMD	-414 K	$ 0.67	7.08 %	$ 624 K	Israel
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Ampio Pharmaceuticals AMPE	-5.01 K	-	-11.43 %	$ 502 K	USA
ANI Pharmaceuticals ANIP	-4.03 M	$ 74.36	-1.64 %	$ 1.44 B	USA
Applied Therapeutics APLT	-27 K	-	-	$ 8.42 M	USA
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
AVEO Pharmaceuticals AVEO	1.6 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	-15.9 M	$ 162.43	0.6 %	$ 8.08 B	USA
BioCryst Pharmaceuticals BCRX	59.3 M	$ 8.49	-0.18 %	$ 1.75 B	USA
BridgeBio Pharma BBIO	43.1 M	$ 65.66	-0.78 %	$ 12.6 B	USA
Brainstorm Cell Therapeutics BCLI	-93 K	-	-2.5 %	$ 5.88 M	USA
BioDelivery Sciences International BDSI	-6 K	-	-4.8 %	$ 255 M	USA
BeiGene, Ltd. BGNE	-42.6 M	-	0.49 %	$ 251 B	Cayman-islands
Bellicum Pharmaceuticals BLCM	2.66 M	-	-9.72 %	$ 5.89 M	USA
Berkeley Lights BLI	910 K	-	-7.31 %	$ 87 M	USA
BioLineRx Ltd. BLRX	9.07 M	$ 2.69	-0.74 %	$ 908 M	Israel
BioMarin Pharmaceutical BMRN	15.3 M	$ 61.3	1.21 %	$ 11.8 B	USA
CymaBay Therapeutics CBAY	18.9 M	-	-	$ 3.45 B	USA